During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...
The following is a summary of “Dose-response relationship between Life's Essential 8 score and COPD risk: the NHANES cohort ...
COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...
Dyspnea, or shortness of breath, is a common COPD symptom. You may experience different levels of dyspnea, but you can take steps to make breathing easier and help preserve your lung health.
In conclusion, COPD is a global disease, with increasing prevalence and health-related impact. The loss of FEV 1 may be slowing down, but what is really needed is an intervention that improves it ...
You must go to a doctor to know for sure whether you have COPD. That’s because there are things to consider for a diagnosis. Some people have asthma and COPD at the same time. If you have ...
Chronic pain is a common complaint among those with COPD. Columnist Caroline Gainer shares the pain relief strategies that ...
Background The natural history and time course of the onset of exacerbation events of chronic obstructive pulmonary disease (COPD) is incompletely understood. Methods A prospective cohort of 212 ...
Chronic obstructive pulmonary disease (COPD) is an irreversible inflammatory disease of the lungs that makes it more difficult to breathe over time. The disease causes changes to the tissues inside ...
Portfolio management is how you set yourself up for long-term financial success and stability. Learn how to square your own investments with your time horizon and risk tolerance. There’s no one ...